The impact of preoperative immune checkpoint inhibitors on kidney and bladder cancer surgeries: a systematic review☆.

Abstract

Therapies based on the use of immune checkpoint inhibitors (ICIs), such as nivolumab, pembrolizumab, ipilimumab, atezolizumab, avelumab, and durvalumab, have proven effective in the treatment of metastatic urological neoplasms. Recently, it has been hypothesized that the use of this type of treatment prior to surgery could lead to an increased difficulty in renal and bladder surgeries. The literature concerning this topic, however, is still scarce and non-consensual. In our systematic review, we used the PRISMA guidelines methodology to search the pertinent literature available up to June 18, 2020 in PubMed. Additionally, we searched the related grey literature in the abstracts of the meetings of the American Society of Clinical Oncology (ASCO), American Society of Clinical Oncology Genitourinary (ASCO-GU), European Society of Medical Oncology (ESMO), and American Urological Association (AUA) from 2015 to 2020. We were able to find only 16 publications that addressed the use of ICIs prior to surgery in kidney and bladder neoplasms. The results were conflicting, and usually the issue of surgical difficulties after the use of ICIs was not directly approached. We hope that our publication may raise the awareness towards the need to further investigate the effects of neoadjuvant ICIs on surgical outcomes in urologic cancers.

• Authors: Aline Petracco Petzold, Fernanda Nascimento Lubianca, Laura Gazal Passos, Carolina Knorst Keppler, Nicole Bernd Becker, Carolina de Mello Viera, André Poisl Fay, Gustavo Franco Carvalhal
• Journal: Current problems in cancer (Curr Probl Cancer) Vol. 46 Issue 1 Pg. 100765 (02 2022) ISSN: 1535-6345 [Electronic] United States
• PMID: 34312011 (Publication Type: Journal Article, Review, Systematic Review)
• Copyright: Copyright © 2021. Published by Elsevier Inc.

Chemical References

• Immune Checkpoint Inhibitors

Topics

• Female
• Humans
• Immune Checkpoint Inhibitors
• Kidney
• Male
• Neoadjuvant Therapy
• Urinary Bladder Neoplasms (drug therapy, surgery)